Cargando…
Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD
BACKGROUND: Lung hyperinflation and exercise intolerance are hallmarks of chronic obstructive pulmonary disease (COPD). However, their relationship remains uncertain. A combined analysis of two placebo-controlled, randomized studies examined the effects of the long-acting muscarinic antagonist umecl...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764300/ https://www.ncbi.nlm.nih.gov/pubmed/29386889 http://dx.doi.org/10.2147/COPD.S145285 |
_version_ | 1783292035363504128 |
---|---|
author | Singh, Sally Maltais, François Tombs, Lee Fahy, William A Vahdati-Bolouri, Mitra Locantore, Nicholas Riley, John H |
author_facet | Singh, Sally Maltais, François Tombs, Lee Fahy, William A Vahdati-Bolouri, Mitra Locantore, Nicholas Riley, John H |
author_sort | Singh, Sally |
collection | PubMed |
description | BACKGROUND: Lung hyperinflation and exercise intolerance are hallmarks of chronic obstructive pulmonary disease (COPD). However, their relationship remains uncertain. A combined analysis of two placebo-controlled, randomized studies examined the effects of the long-acting muscarinic antagonist umeclidinium (UMEC) and long-acting β(2)-agonist vilanterol (VI) separately and in combination on static hyperinflation, exercise endurance time (EET), and their relationship in patients with COPD. METHODS: Patients with moderate-to-severe stable COPD and resting functional residual capacity >120% predicted were randomized to UMEC/VI 62.5/25 μg, UMEC 62.5 μg, VI 25 μg, or placebo for 12 weeks. Inspiratory capacity (IC), residual volume (RV), total lung capacity (TLC), and EET in an endurance shuttle-walk test were measured. In this post hoc analysis, IC/TLC, RV/TLC, and IC were used as hyperinflation markers. RESULTS: After 12 weeks, UMEC/VI and UMEC and VI showed significant improvements in hyperinflation versus placebo when measured by absolute change from baseline in IC/TLC (trough and 3 hours postdose [P≤0.011]). UMEC/VI showed significant improvements versus UMEC and VI in absolute changes in IC/TLC (trough and 3 hours postdose [P≤0.001]). Statistical significance for comparisons with placebo and between treatments for absolute changes in IC and percentage changes in RV/TLC followed similar patterns to those for absolute changes in IC/TLC. UMEC/VI showed significant improvements in EET versus placebo at day 2 and week 12, measured as change from baseline in seconds (P≤0.002) and as a percentage from baseline (P≤0.005). There was a lack of evidence to suggest a correlation between improvements in static hyperinflation and EET at any time point. CONCLUSION: Although the dual bronchodilator UMEC/VI demonstrated greater improvements in static hyperinflation markers than UMEC or VI and significant improvements in exercise endurance, no direct relationship was observed between static hyperinflation and exercise endurance. |
format | Online Article Text |
id | pubmed-5764300 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-57643002018-01-31 Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD Singh, Sally Maltais, François Tombs, Lee Fahy, William A Vahdati-Bolouri, Mitra Locantore, Nicholas Riley, John H Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Lung hyperinflation and exercise intolerance are hallmarks of chronic obstructive pulmonary disease (COPD). However, their relationship remains uncertain. A combined analysis of two placebo-controlled, randomized studies examined the effects of the long-acting muscarinic antagonist umeclidinium (UMEC) and long-acting β(2)-agonist vilanterol (VI) separately and in combination on static hyperinflation, exercise endurance time (EET), and their relationship in patients with COPD. METHODS: Patients with moderate-to-severe stable COPD and resting functional residual capacity >120% predicted were randomized to UMEC/VI 62.5/25 μg, UMEC 62.5 μg, VI 25 μg, or placebo for 12 weeks. Inspiratory capacity (IC), residual volume (RV), total lung capacity (TLC), and EET in an endurance shuttle-walk test were measured. In this post hoc analysis, IC/TLC, RV/TLC, and IC were used as hyperinflation markers. RESULTS: After 12 weeks, UMEC/VI and UMEC and VI showed significant improvements in hyperinflation versus placebo when measured by absolute change from baseline in IC/TLC (trough and 3 hours postdose [P≤0.011]). UMEC/VI showed significant improvements versus UMEC and VI in absolute changes in IC/TLC (trough and 3 hours postdose [P≤0.001]). Statistical significance for comparisons with placebo and between treatments for absolute changes in IC and percentage changes in RV/TLC followed similar patterns to those for absolute changes in IC/TLC. UMEC/VI showed significant improvements in EET versus placebo at day 2 and week 12, measured as change from baseline in seconds (P≤0.002) and as a percentage from baseline (P≤0.005). There was a lack of evidence to suggest a correlation between improvements in static hyperinflation and EET at any time point. CONCLUSION: Although the dual bronchodilator UMEC/VI demonstrated greater improvements in static hyperinflation markers than UMEC or VI and significant improvements in exercise endurance, no direct relationship was observed between static hyperinflation and exercise endurance. Dove Medical Press 2018-01-08 /pmc/articles/PMC5764300/ /pubmed/29386889 http://dx.doi.org/10.2147/COPD.S145285 Text en © 2018 Singh et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Singh, Sally Maltais, François Tombs, Lee Fahy, William A Vahdati-Bolouri, Mitra Locantore, Nicholas Riley, John H Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD |
title | Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD |
title_full | Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD |
title_fullStr | Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD |
title_full_unstemmed | Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD |
title_short | Relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with COPD |
title_sort | relationship between exercise endurance and static hyperinflation in a post hoc analysis of two clinical trials in patients with copd |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5764300/ https://www.ncbi.nlm.nih.gov/pubmed/29386889 http://dx.doi.org/10.2147/COPD.S145285 |
work_keys_str_mv | AT singhsally relationshipbetweenexerciseenduranceandstatichyperinflationinaposthocanalysisoftwoclinicaltrialsinpatientswithcopd AT maltaisfrancois relationshipbetweenexerciseenduranceandstatichyperinflationinaposthocanalysisoftwoclinicaltrialsinpatientswithcopd AT tombslee relationshipbetweenexerciseenduranceandstatichyperinflationinaposthocanalysisoftwoclinicaltrialsinpatientswithcopd AT fahywilliama relationshipbetweenexerciseenduranceandstatichyperinflationinaposthocanalysisoftwoclinicaltrialsinpatientswithcopd AT vahdatibolourimitra relationshipbetweenexerciseenduranceandstatichyperinflationinaposthocanalysisoftwoclinicaltrialsinpatientswithcopd AT locantorenicholas relationshipbetweenexerciseenduranceandstatichyperinflationinaposthocanalysisoftwoclinicaltrialsinpatientswithcopd AT rileyjohnh relationshipbetweenexerciseenduranceandstatichyperinflationinaposthocanalysisoftwoclinicaltrialsinpatientswithcopd |